Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu systematický přehled, časopisecké články
PubMed
36858728
DOI
10.1016/s1470-2045(22)00752-5
PII: S1470-2045(22)00752-5
Knihovny.cz E-zdroje
- MeSH
- imunoterapie MeSH
- konsensus MeSH
- lékařská onkologie MeSH
- lidé MeSH
- nádory * MeSH
- radiační onkologie * MeSH
- radiochirurgie * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite the increasing use in routine clinical practice, there is little information on the safety of combining SBRT with modern targeted therapy or immunotherapy and a paucity of high-level evidence to guide clinical management. A systematic literature review was performed to identify the toxicity profiles of combined metastases-directed SBRT and targeted therapy or immunotherapy. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was sought about risk mitigation strategies of metastases-directed SBRT combined with targeted therapy or immunotherapy; a potential need for and length of interruption to targeted therapy or immunotherapy around SBRT delivery; and potential adaptations of radiation dose and fractionation. Results of this systematic review and consensus process compile the best available evidence for safe combination of metastases-directed SBRT and targeted therapy or immunotherapy for patients with metastatic or oligometastatic cancer and aim to guide today's clinical practice and the design of future clinical trials.
Department of Oncology Aberdeen Royal Infirmary UK
Department of Oncology and Radiotherapy University Hospital Hradec Králové Czech Republic
Department of Oncology GasthuisZusters Antwerpen Antwerpen Belgium
Department of Oncology University of Turin Turin Italy
Department of Radiation Oncology AZ Groeninge Campus Kennedylaan Kortrijk Belgium
Department of Radiation Oncology Campus Bio Medico University of Rome Rome Italy
Department of Radiation Oncology Careggi University Hospital Florence Italy
Department of Radiation Oncology Catharina Hospital Eindhoven Netherlands
Department of Radiation Oncology Ghent University Hospital and Ghent University Gent Belgium
Department of Radiation Oncology Hôpital Valais Sion Switzerland
Department of Radiation Oncology Hospital Universitario Reina Sofia Cordoba Spain
Department of Radiation Oncology Iridium Netwerk Antwerp Belgium
Department of Radiation Oncology Istituti Clinici Scientifici Maugeri IRCCS Pavia Italy
Department of Radiation Oncology Onze Lieve Vrouwziekenhuis Aalst Belgium
Department of Radiation Oncology Radboud University Medical Center Nijmegen Netherlands
Department of Radiation Oncology University Hospital Zurich Zurich Switzerland
Department of Radiation Oncology Vall d'Hebron University Hospital Barcelona Spain
Institute of Radiation Oncology Cantonal Hospital Graubünden Chur Switzerland
Lung Unit The Royal Marsden London UK
Radiation Oncology Department Santa Lucia General University Hospital Cartagena Spain
Radiotherapy and Radiosurgery Department IRCCS Humanitas Research Hospital Milan Italy
Service Radio Oncologie Neuchåtel Hôpital Network La Chaux de Fonds Switzerland
Citace poskytuje Crossref.org